Straumann stock holds steady as investors focus on recent growth figures

Straumann stock is trading close to the 95.00 CHF mark on SIX as of September 4, 2026, with investors looking at recent revenue growth and margins from the latest results.

Straumann stock (ISIN CH0012280076) is trading around 95.00 CHF on the SIX Swiss Exchange as of September 4, 2026, after moving only modestly during the morning session according to market data from finanzen.ch.

Market snapshot and recent price action

According to data compiled by finanzen.ch, Straumann shares were quoted at 95.00 CHF on SIX around midday on September 4, 2026, with the portal listing a last price of 95.06 CHF and a small intraday decline of 0.46%.

Earlier in the session, a separate market update from finanzen.ch reported that Straumann stock edged up by 0.2% to 95.24 CHF in morning trading, reaching an intraday high of 95.40 CHF after opening at 95.02 CHF on the same day.

For investors, these levels place Straumann close to the psychologically important 95.00 CHF mark, while the relatively small intraday moves underline a period of consolidation after earlier gains driven by revenue growth and profitability improvements reported in the latest financial statements.

Recent financial performance and growth drivers

Straumann Holding AG is a leading global provider of dental implants and orthodontic solutions, and its recent financial performance has been characterized by solid revenue growth and robust margins in its latest reported half-year and full-year figures, which cover fiscal periods within the last two years relative to September 4, 2026.

In its most recent interim report for the first half of fiscal year 2026, Straumann reported that group revenue increased at a double digit rate compared with the prior-year period, reflecting continued demand for implant solutions and clear aligner products in key markets such as Europe, North America and Asia.

According to the company’s latest published financial overview, revenue in the most recent full fiscal year is clearly above the level reported two years earlier, with growth in excess of 10% supported by expanding volumes in premium implants and an increasing contribution from digital dentistry offerings.

Management has also highlighted that operating profitability improved in the latest reporting period, with an increase in the operating margin compared with the prior year, supported by scale effects and disciplined cost control, even as Straumann continues to invest in research, development and commercial capabilities.

For investors, the combination of revenue growth and margin resilience is a central theme: the most recent guidance indicates that Straumann aims to maintain double digit revenue growth for the current fiscal year while safeguarding profitability through efficiency initiatives and portfolio mix management.

Valuation context and peer comparison

At a share price around 95.00 CHF on September 4, 2026, Straumann’s market valuation reflects both its strong position in dental implants and the expectations for continued growth in orthodontics and digital dentistry.

The stock is listed on SIX Swiss Exchange and is part of the Swiss large cap universe, often compared with other health care and medical technology names in Switzerland that benefit from structural demand for specialized treatments.

Compared with the broader Swiss stock market, which according to a same day overview on finanzen.ch shows the Swiss Market Index (SMI) level at 14,376.99 points as of September 4, 2026, Straumann’s relatively muted intraday move of less than one percent indicates that company-specific factors rather than broad index swings are currently driving investor attention.

Over the last reported year, Straumann’s share price performance has been underpinned by earnings growth and a solid balance sheet, and the valuation multiples embedded in the current price reflect a premium to more mature medtech peers due to Straumann’s higher expected growth trajectory in implants and clear aligners.

Dental implants as a core product line

Straumann’s core business is dental implants, which are used by dentists and oral surgeons to replace missing teeth and restore chewing function and aesthetics.

Through its premium Straumann brand and associated product lines, the company offers implant systems, prosthetic components and digital workflows that are designed to provide predictable long term outcomes for patients.

Demand for full mouth dental implants and other complex treatments continues to grow, supported by demographic trends such as aging populations and rising awareness of oral health, and Straumann aims to capture this growth through innovation and partnerships with dental clinics worldwide.

Straumann stock price and investor view

As of September 4, 2026, Straumann stock is quoted at around 95.00 CHF on SIX Swiss Exchange, with intraday movements within a narrow band between the opening level of 95.02 CHF and an early high of 95.40 CHF according to finanzen.ch.

For investors, the current price level and recent consolidation phases reflect a balance between the strong fundamental backdrop and the need to monitor how future earnings reports confirm the growth and margin narrative.

Straumann stock key data

• Company: Straumann Holding AG
• ISIN: CH0012280076
• Ticker: STMN
• Trading venue: SIX Swiss Exchange
• Price (as of September 4, 2026): 95.00 CHF
• Sector / Industry: Health Care / Medical Technology
• Index membership: Swiss large cap universe